Quanterix Falls Short in Q2, Cuts 2026 Revenue Outlook by 15%, and Delays Breakeven to 2027
QTRX is trading near its 52-week low of $2.395 (7.7% above the low).
Summary
Quanterix missed Q2 revenue expectations, slashed full-year 2026 revenue guidance by ~15%, and delayed its cash flow breakeven target to 2027, while recording a $26.9M goodwill impairment.
Key Events · Earnings and Guidance · QTRX
-
Q2 Revenue Miss
Revenue of $32.9M grew 34% YoY but fell short of expectations, with legacy Quanterix product revenue declining $2.7M due to weaker academic and pharma demand.
-
Full-Year Guidance Cut
2026 revenue guidance reduced by approximately 15%, reflecting a constrained capital funding environment and slower-than-expected commercial traction.
-
Breakeven Timeline Pushed to 2027
Cash flow breakeven target moved from year-end 2026 to 2027, driven by increased investments in commercial leadership, diagnostics infrastructure, and weaker H1 revenue.
-
$26.9M Goodwill Impairment
A goodwill impairment charge of $26.9 million was recorded for the Akoya acquisition, reflecting lower revenue projections and a decline in the company's market valuation.
Analysis · QTRX · Industrial Applications And Services
Quanterix delivered Q2 revenue of $32.9 million, a 34% year-over-year increase that nonetheless missed expectations. The company lowered its full-year 2026 revenue guidance by roughly 15% and pushed its cash flow breakeven target from year-end 2026 to 2027, pointing to stepped-up commercial investments and a softer first-half top line. A $26.9 million goodwill impairment tied to the Akoya acquisition added to the pressure. While the stock is likely to react negatively to the guidance cut and extended path to profitability, the completed Akoya integration and $85 million in annualized cost synergies offer some operational clarity.
At the time of this filing, QTRX was trading at $2.58 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $189.8M. The 52-week trading range was $2.40 to $8.77. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.